Why Aptinyx Stock Is Soaring Today

George Budwell, The Motley Fool
·2 min read
Why Aptinyx Stock Is Soaring Today
Why Aptinyx Stock Is Soaring Today

The drugmaker's stock is ripping higher in response to a positive midstage trial for its post-traumatic stress disorder (PTSD) candidate known as NYX-783. Before the opening bell, Aptinyx announced that NYX-783 exhibited statistically significant and clinically meaningful efficacy results in a midstage trial consisting of 153 patients with PTSD. PTSD affects over 8.5 million Americans.